Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other agents to treat human immunodeficiency virus (HIV) infection. Efavirenz treatment is associated with a low frequency of serum enzyme elevations1. To understand the hepatotoxicity mechanisms underlying clinically observed liver signals, efavirenz was represented
in DILIsym®, a QST model of DILI.
Presented at ACoP 11 Virtual Conference, Nov. 9-13, 2020
By Diane M. Longo, Kyunghee Yang, Brett A. Howell, Jeffrey L. Woodhead